^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Avastin (bevacizumab)

    i
    Other names: R 435, RG435, R435, rhuMAb-VEGF, RO-4876646
    Company:
    Roche
    Drug class:
    VEGF-A inhibitor
    Related drugs:
    21h
    PRO1184-001: PRO1184 for Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=374, Recruiting, ProfoundBio US Co. | N=134 --> 374 | Trial completion date: Sep 2025 --> Apr 2026 | Trial primary completion date: Jan 2025 --> Oct 2025
    Enrollment change • Trial completion date • Trial primary completion date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • FOLR1 ( Folate receptor alpha )
    |
    HR positive • HER-2 negative • FOLR1 expression • HR positive + HER-2 negative • PTEN mutation + HR positive
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • carboplatin • rinatabart sesutecan (PRO1184)
    1d
    A phase I/II study of nintedanib and capecitabine for refractory metastatic colorectal cancer. (PubMed, JNCI Cancer Spectr)
    The combination of nintedanib and capecitabine is well tolerated. Clinical efficacy appears to be superior to regorafenib or tipiracil hydrochloride monotherapy. Further investigation of similar combinations is warranted.
    P1/2 data • Clinical Trial,Phase I • Clinical Trial,Phase II • Journal • Metastases
    |
    SPP1 (Secreted Phosphoprotein 1)
    |
    Avastin (bevacizumab) • capecitabine • Stivarga (regorafenib) • nintedanib
    2d
    Ensartinib in Combination With Bevacizumab in ALK-positive NSCLC Patients With TP53 Mutation (clinicaltrials.gov)
    P2, N=58, Recruiting, Sun Yat-sen University | Not yet recruiting --> Recruiting | Trial primary completion date: Nov 2023 --> Jun 2024
    Enrollment open • Trial primary completion date • Combination therapy • Metastases
    |
    ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53)
    |
    TP53 mutation • ALK positive • ALK mutation
    |
    Avastin (bevacizumab) • Ensacove (ensartinib)
    2d
    Sintilimab Plus Bevacizumab and SIRT for Intermediate-advanced HCC (clinicaltrials.gov)
    P2, N=23, Not yet recruiting, Second Affiliated Hospital of Guangzhou Medical University
    New P2 trial • Metastases
    |
    Avastin (bevacizumab) • Tyvyt (sintilimab)
    2d
    A Phase II Study of Pulse Reduced Dose Rate Radiation Therapy With Bevacizumab (clinicaltrials.gov)
    P2, N=49, Active, not recruiting, University of Wisconsin, Madison | Recruiting --> Active, not recruiting | N=80 --> 49 | Trial completion date: Dec 2026 --> Dec 2025 | Trial primary completion date: Dec 2025 --> Dec 2024
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    Avastin (bevacizumab)
    3d
    Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer (clinicaltrials.gov)
    P1/2, N=127, Not yet recruiting, National Cancer Institute (NCI)
    New P1/2 trial
    |
    Avastin (bevacizumab) • paclitaxel • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • tolinapant (ASTX660)
    3d
    Sequential AG and mFOLFOX Combined With Serplulimab Injection and Bevacizumab Injection in Untreated Advanced Pancreatic Cancer (clinicaltrials.gov)
    P2, N=37, Recruiting, Zhejiang Cancer Hospital
    New P2 trial • Metastases
    |
    PD-L1 expression
    |
    Avastin (bevacizumab) • albumin-bound paclitaxel • oxaliplatin • Hansizhuang (serplulimab)
    4d
    ABC-lung: Atezolizumab, Bevacizumab and Chemotherapy in EGFR-mutant Non-small Cell Lung Carcinoma (clinicaltrials.gov)
    P2, N=95, Active, not recruiting, ETOP IBCSG Partners Foundation | Trial completion date: Mar 2024 --> Dec 2024 | Trial primary completion date: Mar 2024 --> Dec 2024
    Trial completion date • Trial primary completion date
    |
    EGFR mutation • EGFR L858R • EGFR T790M • EGFR G719X • EGFR S768I
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • carboplatin • paclitaxel • pemetrexed
    4d
    CAPOX + Bevacizumab + Tirelizumab Treating PDL1 CPS < 5 GEA (clinicaltrials.gov)
    P2, N=30, Recruiting, Chinese PLA General Hospital | Trial completion date: Oct 2023 --> Jun 2025 | Trial primary completion date: Apr 2023 --> Dec 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    HER-2 negative
    |
    Avastin (bevacizumab) • Tevimbra (tislelizumab) • capecitabine • oxaliplatin
    4d
    Retifanlimab and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent Gliomas (clinicaltrials.gov)
    P2, N=51, Active, not recruiting, Washington University School of Medicine | Trial primary completion date: Apr 2024 --> Jul 2024
    Trial primary completion date • Combination therapy
    |
    Avastin (bevacizumab) • Zynyz (retifanlimab-dlwr) • epacadostat (INCB024360)
    5d
    A Study to Investigate Ompenaclid Combined With FOLFIRI Plus Bevacizumab in Advanced/Metastatic Colorectal Cancer (clinicaltrials.gov)
    P2, N=70, Recruiting, Inspirna, Inc. | N=50 --> 70
    Enrollment change • Combination therapy • Metastases
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR • RAS mutation
    |
    Avastin (bevacizumab) • 5-fluorouracil • irinotecan • leucovorin calcium • ompenaclid (RGX-202)
    7d
    An integrated omics approach highlights how epigenetic events can explain and predict response to neoadjuvant chemotherapy and bevacizumab in breast cancer. (PubMed, Mol Oncol)
    Using tumor purity computed from copy number data, we developed a method for estimating cancer cell-specific methylation to confirm that the association to response reflects DNA methylation in cancer cells. Taken together, these results support the potential for clinical benefit of the addition of bevacizumab to chemotherapy when administered to the correct patients.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    ER positive • HER-2 negative
    |
    Avastin (bevacizumab)
    8d
    The predictive value of next generation sequencing for matching advanced hepatocellular carcinoma patients to targeted and immunotherapy. (PubMed, Front Immunol)
    However, treatment of Atezolizumab and Bevacizumab appeared to provide longer OS in the high-risk group (12 months vs 9.2, 9, or 5 months for other treatments, p<0.001). The prognostic model constructed by PD-L1, TMB, TERT, and TP53 can identify aHCC patients who would benefit from targeted and immunotherapy, providing insights for the personalized treatment of HCC.
    Journal • Next-generation sequencing • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker • Metastases
    |
    PD-L1 (Programmed death ligand 1) • TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • TERT (Telomerase Reverse Transcriptase)
    |
    PD-L1 expression • TP53 wild-type
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab)
    8d
    Efficacy and Safety of VB10.16 Alone or in Combination With Atezolizumab in Patients With Advanced Cervical Cancer. (clinicaltrials.gov)
    P2; Not yet recruiting --> Recruiting | Initiation date: Dec 2023 --> Apr 2024
    Combination therapy • Enrollment open • Trial initiation date • PD(L)-1 companion diagnostic • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    VENTANA PD-L1 (SP263) Assay
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • Tecentriq (atezolizumab) • VB10.16
    8d
    Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent Glioblastoma (clinicaltrials.gov)
    P2, N=60, Active, not recruiting, Dana-Farber Cancer Institute | Trial completion date: Feb 2024 --> Jun 2024
    Trial completion date
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab)
    9d
    CodeBreak101: Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) (clinicaltrials.gov)
    P1/2, N=1126, Recruiting, Amgen | Trial primary completion date: Sep 2026 --> Dec 2026
    Trial primary completion date • Combination therapy • Metastases
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • Mekinist (trametinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Ibrance (palbociclib) • carboplatin • paclitaxel • docetaxel • everolimus • Vectibix (panitumumab) • Lumakras (sotorasib) • pemetrexed • oxaliplatin • irinotecan • batoprotafib (TNO155) • vociprotafib (RMC-4630) • BI 1701963 • zeluvalimab (AMG 404)
    9d
    Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) (clinicaltrials.gov)
    P2, N=531, Recruiting, AstraZeneca | Trial completion date: Mar 2025 --> Aug 2026 | Trial primary completion date: Mar 2025 --> Aug 2026
    Trial completion date • Trial primary completion date • Combination therapy • Pan tumor • Metastases
    |
    Avastin (bevacizumab) • carboplatin • Imfinzi (durvalumab) • 5-fluorouracil • capecitabine • leucovorin calcium • datopotamab deruxtecan (DS-1062a) • saruparib (AZD5305) • rilvegostomig (AZD2936) • volrustomig (MEDI5752)
    9d
    A Study of AK104（ an Anti-PD-1 and Anti-CTLA-4 Bispecific Antibody) in Recurrent or Metastatic Cervical Cancer (clinicaltrials.gov)
    P2, N=50, Completed, Akeso | Active, not recruiting --> Completed | Trial completion date: Jun 2023 --> Feb 2024 | Trial primary completion date: Dec 2022 --> Feb 2024
    Trial completion • Trial completion date • Trial primary completion date • Metastases
    |
    Avastin (bevacizumab) • cisplatin • carboplatin • paclitaxel • Kaitanni (cadonilimab)
    9d
    Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease (clinicaltrials.gov)
    P1, N=155, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Mar 2024 --> Mar 2026 | Trial primary completion date: Mar 2024 --> Mar 2026
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    Avastin (bevacizumab) • Erbitux (cetuximab) • Torisel (temsirolimus)
    9d
    Biomarker-driven targeted therapy in patients with recurrent platinum-resistant epithelial ovarian cancer (BRIGHT): protocol for an open-label, multicenter, umbrella study. (PubMed, Int J Gynecol Cancer)
    To evaluate the efficacy and safety of biomarker-driven combinatorial therapies of pamiparib, tislelizumab, bevacizumab, and nab-paclitaxel in platinum-resistant, recurrent ovarian cancer. Recruitment is estimated to be completed by 2024 and results may be published by 2027. ClinicalTrials.gov: NCT05044871.
    Journal • BRCA Biomarker • PARP Biomarker • PD(L)-1 Biomarker • IO biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • CD8 (cluster of differentiation 8)
    |
    BRCA2 mutation • BRCA1 mutation • BRCA wild-type
    |
    Avastin (bevacizumab) • Tevimbra (tislelizumab) • albumin-bound paclitaxel • Partruvix (pamiparib)
    9d
    Real-world outcomes and molecular correlates of incorporating immunotherapy (IO) and bevacizumab (Bev) in treating patients with peritoneal mesothelioma (PeM): A comparative analysis with pleural mesothelioma (PM). (ASCO 2024)
    No abstracts available
    Real-world evidence • Clinical • Real-world
    |
    Avastin (bevacizumab)
    9d
    ID1high/activin Ahigh glioblastoma cells contribute to resistance to anti-angiogenesis therapy through malformed vasculature. (PubMed, Cell Death Dis)
    Although bevacizumab (BVZ), a representative drug for anti-angiogenesis therapy (AAT), is used as a first-line treatment for patients with glioblastoma (GBM), its efficacy is notably limited...Using a GBM mouse model, we demonstrated that AAT resistance can be overcome by administering therapy based on a combination of BVZ and SB431542, a Smad2/3 inhibitor, which contributed to enhancing survival. These findings offer valuable insights that could contribute to the development of new strategies for treating AAT-resistant GBM.
    Journal
    |
    SNAI2 (Snail Family Transcriptional Repressor 2) • SMAD2 (SMAD Family Member 2) • SMAD3 (SMAD Family Member 3)
    |
    Avastin (bevacizumab)
    11d
    Racial disparities in outcomes of patients with stage I-III triple-negative breast cancer after adjuvant chemotherapy: a post-hoc analysis of the E5103 randomized trial. (PubMed, Breast Cancer Res Treat)
    This clinical trial population of similarly treated TNBC patients showed no racial differences in breast cancer outcomes. Disease extent, rather than race, was associated with disease events.
    Retrospective data • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    Avastin (bevacizumab)
    11d
    DeFianCe: Phase 2 Study of DKN-01 in Colorectal Cancer (clinicaltrials.gov)
    P2, N=150, Recruiting, Leap Therapeutics, Inc. | Trial completion date: Aug 2024 --> Dec 2025 | Trial primary completion date: Mar 2024 --> Dec 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    Avastin (bevacizumab) • 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium • sirexatamab (DKN-01)
    11d
    Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age (clinicaltrials.gov)
    P1/2, N=20, Recruiting, University of Miami | Initiation date: May 2024 --> Aug 2024
    Trial initiation date
    |
    Avastin (bevacizumab) • Erbitux (cetuximab)
    11d
    BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma (clinicaltrials.gov)
    P3, N=401, Active, not recruiting, ETOP IBCSG Partners Foundation | Trial completion date: Jan 2024 --> Jun 2024 | Trial primary completion date: Jan 2024 --> Jun 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • carboplatin • pemetrexed
    12d
    The Safety and Effectiveness of Bevacizumab in Metastatic Colorectal Cancer With Unresectable Metastases: A Real-Life Study From the South of Morocco. (PubMed, Cureus)
    In the first line, all patients received bi-chemotherapy plus bevacizumab, i.e., fluorouracil, oxaliplatin, and leucovorin in 34 (20.9%) patients; capecitabine plus oxaliplatin in 88 (54.3%) patients; leucovorin, fluorouracil, and irinotecan in 17 (10.4%) patients; and capecitabine plus irinotecan in 23 (14.1%) patients. With the new healthcare and social security systems, easier access to expensive treatments and molecular pathology tests is currently available. It is important to highlight that real-world data can offer valuable insights into the daily clinical practice of medical oncology.
    Journal • Metastases
    |
    EGFR (Epidermal growth factor receptor)
    |
    Avastin (bevacizumab) • 5-fluorouracil • capecitabine • oxaliplatin • irinotecan • leucovorin calcium
    12d
    Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC (clinicaltrials.gov)
    P2, N=111, Recruiting, Peking University Cancer Hospital & Institute | Not yet recruiting --> Recruiting | Initiation date: Apr 2024 --> Jan 2024
    Enrollment open • Trial initiation date
    |
    Avastin (bevacizumab) • AiRuiKa (camrelizumab) • AiTan (rivoceranib) • adebrelimab (SHR-1316)
    12d
    Status of HRD That Lead to a Benefit From Olaparib in Combination With Bevacizumab (STROBE Trial) (clinicaltrials.gov)
    P2; N=100; Recruiting; Sponsor:Vall d'Hebron Institute of Oncology
    Combination therapy • New P2 trial • Metastases
    |
    HRD (Homologous Recombination Deficiency)
    |
    HRD
    |
    SOPHiA DDM HRD Solution
    |
    Avastin (bevacizumab) • Lynparza (olaparib)
    12d
    Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial (clinicaltrials.gov)
    P3, N=408, Recruiting, ECOG-ACRIN Cancer Research Group | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Avastin (bevacizumab) • Erbitux (cetuximab) • Vectibix (panitumumab) • oxaliplatin • irinotecan • leucovorin calcium • fluorouracil topical
    14d
    Secondary cytoreductive surgery and oncologic outcomes in the era of targeted maintenance therapy for recurrent, platinum-sensitive ovarian cancer. (PubMed, Gynecol Oncol)
    CGR during SCS is associated with improved PFS2 compared to suboptimal resection. Prospective randomized trials are warranted to elucidate the role of SCS as more therapeutics become available.
    Journal • Surgery
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    BRCA2 mutation
    |
    Avastin (bevacizumab)
    15d
    Complete remission in a pretreated, microsatellite-stable, KRAS-mutated colon cancer patient after treatment with sintilimab and bevacizumab and platinum-based chemotherapy: a case report and literature review. (PubMed, Front Immunol)
    He has achieved a progression-free survival of 43 months and is still being followed up at our center. The above results suggest that this therapeutic regimen is a promising treatment modality for the management of pretreated, MSS-type and KRAS-mutated metastatic colorectal cancer although its application to the general public still needs to be validated in clinical trials.
    Clinical • Clinical guideline • Retrospective data • Review • Clinical Trial,Phase III • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    KRAS (KRAS proto-oncogene GTPase) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • CD14 (CD14 Molecule)
    |
    KRAS mutation
    |
    Avastin (bevacizumab) • Tyvyt (sintilimab)
    15d
    Fluorescence Guided Surgery in Breast Cancer - The MARGIN-2 Study (clinicaltrials.gov)
    P=N/A, N=70, Recruiting, University Medical Center Groningen | Not yet recruiting --> Recruiting | Phase classification: P2/3 --> PN/A | Trial completion date: Jul 2024 --> Dec 2024 | Trial primary completion date: Mar 2024 --> Sep 2024
    Enrollment open • Phase classification • Trial completion date • Trial primary completion date • Surgery
    |
    Avastin (bevacizumab)
    16d
    Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC (clinicaltrials.gov)
    P2, N=71, Recruiting, University of Wisconsin, Madison | N=110 --> 71
    Enrollment change • Metastases
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog) • MSI (Microsatellite instability)
    |
    BRAF mutation • BRAF V600
    |
    Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • Vectibix (panitumumab) • irinotecan • leucovorin calcium
    16d
    BIS-Program: Impact of Neoadjuvant Immunotherapy in Early Stage Breast Cancer Before Standard Therapy (clinicaltrials.gov)
    P2, N=185, Recruiting, Gustave Roussy, Cancer Campus, Grand Paris | Trial completion date: Feb 2025 --> Feb 2026 | Trial primary completion date: Feb 2024 --> Feb 2025
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor) • GZMB (Granzyme B)
    |
    HER-2 positive • HER-2 overexpression • HER-2 amplification
    |
    Avastin (bevacizumab) • Herceptin (trastuzumab) • Tecentriq (atezolizumab) • Perjeta (pertuzumab)
    16d
    SHR-8068 Combined With Adbelizumab and BP102 in the Treatment of Advanced Colorectal Cancer (clinicaltrials.gov)
    P1/2, N=36, Not yet recruiting, West China Hospital
    New P1/2 trial • Metastases
    |
    Avastin (bevacizumab) • SHR-8068 • adebrelimab (SHR-1316)
    17d
    Exploring management and outcomes of elderly patients with glioblastoma using data from two randomised trials (GEINO1401/EX-TEM). (PubMed, J Neurooncol)
    In this trial population of predominantly fit EP, survival was similar to YP despite a proportion receiving less aggressive therapy at diagnosis and recurrence. Advancing age does not appear to be an adverse prognostic factor for glioblastoma when patients are fit for treatment, and a less aggressive approach in selected patients may not compromise outcomes.
    Journal
    |
    MGMT (6-O-methylguanine-DNA methyltransferase)
    |
    Avastin (bevacizumab) • temozolomide
    17d
    Neo-Sequence 2：NCT Plus Anti-angiogenesis Therapy and Immunotherapy for LADGC (clinicaltrials.gov)
    P2, N=67, Recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
    New P2 trial • Metastases
    |
    Avastin (bevacizumab) • albumin-bound paclitaxel
    18d
    BOUQUET: A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors (clinicaltrials.gov)
    P2, N=550, Active, not recruiting, Hoffmann-La Roche | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    ER (Estrogen receptor)
    |
    Avastin (bevacizumab) • Lynparza (olaparib) • Tecentriq (atezolizumab) • Ibrance (palbociclib) • paclitaxel • Kadcyla (ado-trastuzumab emtansine) • Cotellic (cobimetinib) • Verzenio (abemaciclib) • cyclophosphamide • letrozole • ipatasertib (RG7440) • triptorelin • goserelin acetate • giredestrant (GDC-9545) • inavolisib (GDC-0077)
    18d
    Neo-Sequence 1: Neoadjuvant Chemotherapy With or Without Antiangiogenesis and Sequential Immunotherapy for HER2-negative MMR-proficient Locally Advanced Gastric or Gastroesophageal Adenocarcinoma (clinicaltrials.gov)
    P=N/A, N=70, Completed, Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Recruiting --> Completed | Trial completion date: May 2025 --> Dec 2023 | Trial primary completion date: May 2025 --> Dec 2023
    Trial completion • Trial completion date • Trial primary completion date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • paclitaxel • Tyvyt (sintilimab) • albumin-bound paclitaxel • oxaliplatin
    18d
    PRIDE: Protective VEGF Inhibition for Isotoxic Dose Escalation in Glioblastoma (clinicaltrials.gov)
    P2, N=146, Recruiting, Ludwig-Maximilians - University of Munich | Not yet recruiting --> Recruiting | Phase classification: P2a --> P2 | Trial completion date: Jan 2027 --> Jul 2027 | Initiation date: Oct 2023 --> Apr 2024 | Trial primary completion date: Oct 2026 --> Apr 2027
    Enrollment open • Phase classification • Trial completion date • Trial initiation date • Trial primary completion date
    |
    MGMT (6-O-methylguanine-DNA methyltransferase)
    |
    IDH wild-type
    |
    Avastin (bevacizumab)
    19d
    Status of alternative angiogenic pathways in glioblastoma resected under and after bevacizumab treatment. (PubMed, Brain Tumor Pathol)
    PLGF was more abundant in T2 diffuse/circumscribe patterns (p = 0.046). This is the first study to evaluate angiogenic factors other than VEGF during effective and refractory Bev therapy in patient-derived specimens.
    Journal
    |
    EPHA2 (EPH receptor A2) • FGF2 (Fibroblast Growth Factor 2)
    |
    Avastin (bevacizumab)